{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:25:59Z","timestamp":1787570759947,"version":"build-2736575974"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11064-026-04845-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:03:34Z","timestamp":1785733414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nicotine in Neurodegenerative and Neuropsychiatric Disorders: Mechanisms and Clinical Evidence"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-3935","authenticated-orcid":false,"given":"Geir","family":"Bj\u00f8rklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Gurgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"4845_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.pharmtox.48.113006.094742","volume":"49","author":"NL Benowitz","year":"2009","unstructured":"Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57\u201371","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"4845_CR2","volume":"15","author":"H Grezenko","year":"2023","unstructured":"Grezenko H, Ekhator C, Nwabugwu NU, Ganga H, Affaf M, Abdelaziz AM, Rehman A, Shehryar A, Abbasi FA, Bellegarde SB, Khaliq AS (2023) Epigenetics in neurological and psychiatric disorders: a comprehensive review of current understanding and future perspectives. Cureus 15(8):e43960","journal-title":"Cureus"},{"key":"4845_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914570","author":"L Sansone","year":"2023","unstructured":"Sansone L, Milani F, Fabrizi R, Belli M, Cristina M, Zag\u00e0 V, de Iure A, Cicconi L, Bonassi S, Russo P (2023) Nicotine: from discovery to biological effects. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241914570","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4845_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrn2849","volume":"11","author":"JP Changeux","year":"2010","unstructured":"Changeux JP (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11(6):389\u2013401","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"4845_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","volume":"84","author":"MR Picciotto","year":"2008","unstructured":"Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not either\/or: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84(4):329\u2013342","journal-title":"Prog Neurobiol"},{"key":"4845_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.irn.2015.07.001","volume":"124","author":"JA Dani","year":"2015","unstructured":"Dani JA (2015) Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int Rev Neurobiol 124:3\u201319","journal-title":"Int Rev Neurobiol"},{"key":"4845_CR7","unstructured":"Ramachandran Nair L, Liu X (2019) Targeting the \u03b14\u03b22- and \u03b17-subtypes of nicotinic acetylcholine receptors for smoking cessation medication development. J Addict Res Ther 10(2)"},{"issue":"4","key":"4845_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/pr.110.003269","volume":"63","author":"M Quik","year":"2011","unstructured":"Quik M, Wonnacott S (2011) \u03b16\u03b22* and \u03b14\u03b22* nicotinic acetylcholine receptors as drug targets for Parkinson\u2019s disease. Pharmacol Rev 63(4):938\u2013966","journal-title":"Pharmacol Rev"},{"issue":"12","key":"4845_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.bmcl.2005.04.036","volume":"15","author":"JW Coe","year":"2005","unstructured":"Coe JW, Vetelino MG, Bashore CG, Wirtz MC, Brooks PR, Arnold EP, Lebel LA, Fox CB, Sands SB, Davis TI, Schulz DW, Rollema H, Tingley FD 3rd;, O\u2019Neill BT (2005) In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 15(12):2974\u20132979","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"4845_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","volume":"28","author":"H Rollema","year":"2007","unstructured":"Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007) Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28(7):316\u2013325","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4845_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2014.01.029","volume":"89","author":"RL Papke","year":"2014","unstructured":"Papke RL (2014) Merging old and new perspectives on nicotinic acetylcholine receptors. Biochem Pharmacol 89(1):1\u201311","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4845_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1517\/14728222.2013.736498","volume":"17","author":"TL Wallace","year":"2013","unstructured":"Wallace TL, Bertrand D (2013) Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets 17(2):139\u2013155","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"4845_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1124\/pr.108.000562","volume":"61","author":"SD Buckingham","year":"2009","unstructured":"Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer\u2019s disease and amyloid neuroprotection. Pharmacol Rev 61(1):39\u201361","journal-title":"Pharmacol Rev"},{"key":"4845_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.649129","volume":"15","author":"Y Sherafat","year":"2021","unstructured":"Sherafat Y, Bautista M, Fowler CD (2021) Multidimensional intersection of nicotine, gene expression, and behavior. Front Behav Neurosci 15:649129","journal-title":"Front Behav Neurosci"},{"issue":"3","key":"4845_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.neuron.2019.07.030","volume":"104","author":"A Gharpure","year":"2019","unstructured":"Gharpure A, Teng J, Zhuang Y, Noviello CM, Walsh RM, Cabuco R, Howard RJ, Zaveri NT, Lindahl E, Hibbs RE (2019) Agonist Selectivity and Ion Permeation in the \u03b13\u03b24 Ganglionic Nicotinic Receptor. Neuron 104(3):501-511.e506","journal-title":"Neuron"},{"issue":"10","key":"4845_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1176\/appi.ajp.2015.14101266","volume":"172","author":"TE Moffitt","year":"2015","unstructured":"Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, Harrington H, Hogan S, Meier MH, Polanczyk GV, Poulton R, Ramrakha S, Sugden K, Williams B, Rohde LA, Caspi A (2015) Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172(10):967\u2013977","journal-title":"Am J Psychiatry"},{"issue":"3","key":"4845_CR17","first-page":"196","volume":"34","author":"S Prasad","year":"2025","unstructured":"Prasad S, Kumminimana R (2025) Attention-deficit\/hyperactivity disorder: insights, advances and challenges in research and practice. Postep Psychiatr Neurol 34(3):196\u2013206","journal-title":"Postep Psychiatr Neurol"},{"issue":"3","key":"4845_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/1570159X11311030005","volume":"11","author":"I Posadas","year":"2013","unstructured":"Posadas I, L\u00f3pez-Hern\u00e1ndez B, Ce\u00f1a V (2013) Nicotinic receptors in neurodegeneration. Curr Neuropharmacol 11(3):298\u2013314","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"4845_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/ntr\/nty166","volume":"21","author":"AV Terry","year":"2019","unstructured":"Terry AV, Callahan PM (2019) Nicotinic acetylcholine receptor ligands, cognitive function, and preclinical approaches to drug discovery. Nicotine Tob Res 21(3):383\u2013394","journal-title":"Nicotine Tob Res"},{"key":"4845_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2011.00068","author":"J Potashkin","year":"2011","unstructured":"Potashkin J, Seidl SE (2011) The promise of neuroprotective agents in Parkinson\u2019s disease. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2011.00068","journal-title":"Front Neurol"},{"key":"4845_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fimmu.2017.01085","volume":"8","author":"T Fujii","year":"2017","unstructured":"Fujii T, Mashimo M, Moriwaki Y, Misawa H, Ono S, Horiguchi K, Kawashima K (2017) Expression and function of the cholinergic system in immune cells. Front Immunol 8:1085","journal-title":"Front Immunol"},{"issue":"3","key":"4845_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1471-4159.2002.00874.x","volume":"81","author":"A Nordberg","year":"2002","unstructured":"Nordberg A, Hellstr\u00f6m-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J (2002) Chronic nicotine treatment reduces \u03b2-amyloidosis in the brain of a mouse model of Alzheimer\u2019s disease (APPsw). J Neurochem 81(3):655\u2013658","journal-title":"J Neurochem"},{"issue":"6","key":"4845_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","volume":"63","author":"A Olincy","year":"2006","unstructured":"Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63(6):630\u2013638","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"4845_CR24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","volume":"165","author":"R Freedman","year":"2008","unstructured":"Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165(8):1040\u20131047","journal-title":"Am J Psychiatry"},{"issue":"12","key":"4845_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1468-1331.2007.01949.x","volume":"14","author":"G Villafane","year":"2007","unstructured":"Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson\u2019s disease: an open trial. Eur J Neurol 14(12):1313\u20131316","journal-title":"Eur J Neurol"},{"issue":"2","key":"4845_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/WNL.0b013e31823efcbb","volume":"78","author":"P Newhouse","year":"2012","unstructured":"Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012) Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 78(2):91\u2013101","journal-title":"Neurology"},{"issue":"2","key":"4845_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s002130050750","volume":"140","author":"ED Levin","year":"1998","unstructured":"Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE (1998) Transdermal nicotine effects on attention. Psychopharmacology 140(2):135\u2013141","journal-title":"Psychopharmacology"},{"issue":"6","key":"4845_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.mp.4001035","volume":"7","author":"RD Shytle","year":"2002","unstructured":"Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7(6):525\u2013535","journal-title":"Mol Psychiatry"},{"key":"4845_CR29","first-page":"37","volume":"4","author":"J Toyohara","year":"2010","unstructured":"Toyohara J, Hashimoto K (2010) \u03b17 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in Schizophrenia and Alzheimer\u2019s disease. Open Med Chem J 4:37\u201356","journal-title":"Open Med Chem J"},{"issue":"3","key":"4845_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.10277","volume":"52","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Takkouche B, Caama\u00f1o-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson\u2019s disease. Ann Neurol 52(3):276\u2013284","journal-title":"Ann Neurol"},{"issue":"3\u20134","key":"4845_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","volume":"184","author":"ED Levin","year":"2006","unstructured":"Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184(3\u20134):523\u2013539","journal-title":"Psychopharmacology"},{"issue":"4","key":"4845_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/0269881104047273","volume":"18","author":"KA Sacco","year":"2004","unstructured":"Sacco KA, Bannon KL, George TP (2004) Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 18(4):457\u2013474","journal-title":"J Psychopharmacol"},{"issue":"5","key":"4845_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tips.2010.12.008","volume":"32","author":"R Polosa","year":"2011","unstructured":"Polosa R, Benowitz NL (2011) Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 32(5):281\u2013289","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4845_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-024-00367-w","volume":"34","author":"CM Hoffman","year":"2024","unstructured":"Hoffman CM, Versluis A, Chirila S, Kirenga BJ, Khan A, Saeed S, Sooronbaev T, Tsiligianni I, Arvind DK, Bauld LC, van den Brand FA, Chavannes NH, Pinnock H, Powell PD, van der Schans J, Siddiqi K, Williams S, van der Kleij MJJR (2024) The FRESHAIR4Life study: global implementation research on non-communicable disease prevention targeting adolescents\u2019 exposure to tobacco and air pollution in disadvantaged populations. NPJ Prim Care Respir Med 34(1):14","journal-title":"NPJ Prim Care Respir Med"},{"key":"4845_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fnagi.2025.1535310","volume":"17","author":"X Lin","year":"2025","unstructured":"Lin X, Li Q, Pu M, Dong H, Zhang Q (2025) Significance of nicotine and nicotinic acetylcholine receptors in Parkinson\u2019s disease. Front Aging Neurosci 17:54","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"4845_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-021-00036-1","volume":"2","author":"SE Desale","year":"2021","unstructured":"Desale SE, Chidambaram H, Chinnathambi S (2021) G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-\u03b2 in Alzheimer\u2019s disease. Mol Biomed 2(1):17","journal-title":"Mol Biomed"},{"issue":"1","key":"4845_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10571-025-01586-6","volume":"45","author":"SM Abraham","year":"2025","unstructured":"Abraham SM, Suresh S, Komal P (2025) Targeting neuronal alpha7 nicotinic acetylcholine receptor upregulation in age-related neurological disorders. Cell Mol Neurobiol 45(1):70","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"4845_CR38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0896-6273(02)00625-6","volume":"33","author":"HD Mansvelder","year":"2002","unstructured":"Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33(6):905\u2013919","journal-title":"Neuron"},{"issue":"2","key":"4845_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.neuron.2011.05.036","volume":"71","author":"SJ Kotowski","year":"2011","unstructured":"Kotowski SJ, Hopf FW, Seif T, Bonci A, von Zastrow M (2011) Endocytosis promotes rapid dopaminergic signaling. Neuron 71(2):278\u2013290","journal-title":"Neuron"},{"issue":"1","key":"4845_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12974-023-02768-z","volume":"20","author":"H Liu","year":"2023","unstructured":"Liu H, Zhang X, Shi P, Yuan J, Jia Q, Pi C, Chen T, Xiong L, Chen J, Tang J, Yue R, Liu Z, Shen H, Zuo Y, Wei Y, Zhao L (2023) \u03b17 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect. J Neuroinflammation 20(1):84","journal-title":"J Neuroinflammation"},{"issue":"6921","key":"4845_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature01339","volume":"421","author":"H Wang","year":"2003","unstructured":"Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421(6921):384\u2013388","journal-title":"Nature"},{"key":"4845_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1490300","volume":"18","author":"FJ Liu","year":"2024","unstructured":"Liu FJ, Wu J, Gong LJ, Yang HS, Chen H (2024) Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives. Front Neurosci 18:1490300","journal-title":"Front Neurosci"},{"key":"4845_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.physbeh.2015.12.008","volume":"155","author":"MG Kutlu","year":"2016","unstructured":"Kutlu MG, Gould TJ (2016) Nicotinic modulation of hippocampal cell signaling and associated effects on learning and memory. Physiol Behav 155:162\u2013171","journal-title":"Physiol Behav"},{"issue":"3\u20134","key":"4845_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.18054\/pb.v121-122i3-4.10547","volume":"121","author":"A Zandona","year":"2020","unstructured":"Zandona A, Katalini\u0107 M (2020) Nicotinic acetylcholine receptors: diversity and physiological importance for neurodegenerative disorders and development of organophosphate antidotes. Periodicum biologorum 121(3\u20134):115\u2013128","journal-title":"Periodicum biologorum"},{"issue":"7","key":"4845_CR45","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1523\/JNEUROSCI.5038-09.2010","volume":"30","author":"CM Hernandez","year":"2010","unstructured":"Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer\u2019s disease. J Neurosci 30(7):2442\u20132453","journal-title":"J Neurosci"},{"issue":"4","key":"4845_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1570159X15666170912110450","volume":"16","author":"M Zoli","year":"2018","unstructured":"Zoli M, Pucci S, Vilella A, Gotti C (2018) Neuronal and extraneuronal nicotinic acetylcholine receptors. Curr Neuropharmacol 16(4):338\u2013349","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"4845_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tips.2004.04.006","volume":"25","author":"F Dajas-Bailador","year":"2004","unstructured":"Dajas-Bailador F, Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 25(6):317\u2013324","journal-title":"Trends Pharmacol Sci"},{"key":"4845_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cellsig.2017.01.024","volume":"41","author":"S Rajagopal","year":"2018","unstructured":"Rajagopal S, Shenoy SK (2018) GPCR desensitization: acute and prolonged phases. Cell Signal 41:9\u201316","journal-title":"Cell Signal"},{"key":"4845_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26206139","author":"T Mizrachi","year":"2021","unstructured":"Mizrachi T, Vaknin-Dembinsky A, Brenner T, Treinin M (2021) Neuroinflammation modulation via \u03b17 nicotinic acetylcholine receptor and its chaperone, RIC-3. Molecules. https:\/\/doi.org\/10.3390\/molecules26206139","journal-title":"Molecules"},{"key":"4845_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1358141","volume":"16","author":"I Ullah","year":"2024","unstructured":"Ullah I, Zhao L, Uddin S, Zhou Y, Wang X, Li H (2024) Nicotine-mediated therapy for Parkinson\u2019s disease in transgenic Caenorhabditis elegans model. Front Aging Neurosci 16:1358141","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"4845_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/2040622310397691","volume":"2","author":"J Kawamata","year":"2011","unstructured":"Kawamata J, Suzuki S, Shimohama S (2011) Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models. Ther Adv Chronic Dis 2(3):197\u2013208","journal-title":"Ther Adv Chronic Dis"},{"key":"4845_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.557647","volume":"13","author":"Y Dong","year":"2020","unstructured":"Dong Y, Bi W, Zheng K, Zhu E, Wang S, Xiong Y, Chang J, Jiang J, Liu B, Lu Z, Cheng Y (2020) Nicotine prevents oxidative stress-induced hippocampal neuronal injury through \u03b17-nAChR\/Erk1\/2 signaling pathway. Front Mol Neurosci 13:557647","journal-title":"Front Mol Neurosci"},{"key":"4845_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1556456","volume":"16","author":"M Delgado","year":"2025","unstructured":"Delgado M, Schuepbach RA, Bartussek J (2025) Opinion: exploring alternative pathways to neuroprotection-nicotine and carbon monoxide as antioxidative factors in neurodegeneration and delirium. Front Neurol 16:1556456","journal-title":"Front Neurol"},{"issue":"13","key":"4845_CR54","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1389450115666141024113925","volume":"15","author":"L Saso","year":"2014","unstructured":"Saso L, Firuzi O (2014) Pharmacological applications of antioxidants: lights and shadows. Curr Drug Targets 15(13):1177\u20131199","journal-title":"Curr Drug Targets"},{"issue":"4","key":"4845_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong XX, Wang Y, Qin ZH (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 30(4):379\u2013387","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4845_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40035-024-00452-7","volume":"13","author":"SK Power","year":"2024","unstructured":"Power SK, Venkatesan S, Qu S, McLaurin J, Lambe EK (2024) Enhanced prefrontal nicotinic signaling as evidence of active compensation in Alzheimer\u2019s disease models. Transl Neurodegener 13(1):58","journal-title":"Transl Neurodegener"},{"issue":"3","key":"4845_CR57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ntr\/nty063","volume":"21","author":"M Quik","year":"2019","unstructured":"Quik M, Boyd JT, Bordia T, Perez X (2019) Potential therapeutic application for nicotinic receptor drugs in movement disorders. Nicotine Tob Res 21(3):357\u2013369","journal-title":"Nicotine Tob Res"},{"key":"4845_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1179611","author":"V Echeverria","year":"2023","unstructured":"Echeverria V, Mendoza C, Iarkov A (2023) Nicotinic acetylcholine receptors and learning and memory deficits in neuroinflammatory diseases. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2023.1179611","journal-title":"Front Neurosci"},{"key":"4845_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00082","volume":"14","author":"T Yang","year":"2020","unstructured":"Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, Yu S, Liu H (2020) The role of BDNF on neural plasticity in depression. Front Cell Neurosci 14:82","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"4845_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-010-1932-6","volume":"212","author":"NS Philip","year":"2010","unstructured":"Philip NS, Carpenter LL, Tyrka AR, Price LH (2010) Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology 212(1):1\u201312","journal-title":"Psychopharmacology"},{"issue":"Pt B","key":"4845_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuropharm.2014.12.028","volume":"96","author":"MR Picciotto","year":"2015","unstructured":"Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS (2015) Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states. Neuropharmacology 96(Pt B):235\u2013243","journal-title":"Neuropharmacology"},{"key":"4845_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnmol.2012.00083","volume":"5","author":"AA Feduccia","year":"2012","unstructured":"Feduccia AA, Chatterjee S, Bartlett SE (2012) Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions. Front Mol Neurosci 5:83","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"4845_CR63","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto MR, Higley MJ, Mineur YS (2012) Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76(1):116\u2013129","journal-title":"Neuron"},{"issue":"6","key":"4845_CR64","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archpsyc.62.6.649","volume":"62","author":"KA Sacco","year":"2005","unstructured":"Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62(6):649\u2013659","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"4845_CR65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.pbb.2007.09.014","volume":"88","author":"AS Potter","year":"2008","unstructured":"Potter AS, Newhouse PA (2008) Acute nicotine improves cognitive deficits in young adults with attention-deficit\/hyperactivity disorder. Pharmacol Biochem Behav 88(4):407\u2013417","journal-title":"Pharmacol Biochem Behav"},{"issue":"13","key":"4845_CR66","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/npp.2015.176","volume":"40","author":"RS Keefe","year":"2015","unstructured":"Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC (2015) Randomized, double-blind, placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40(13):3053\u20133060","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4845_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3831\/KPI.2020.23.001","volume":"23","author":"RK Tiwari","year":"2020","unstructured":"Tiwari RK, Sharma V, Pandey RK, Shukla SS (2020) Nicotine addiction: neurobiology and mechanism. J Pharmacopunct 23(1):1\u20137","journal-title":"J Pharmacopunct"},{"issue":"3","key":"4845_CR68","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1111\/ejn.14160","volume":"50","author":"C Morel","year":"2019","unstructured":"Morel C, Montgomery S, Han MH (2019) Nicotine and alcohol: the role of midbrain dopaminergic neurons in drug reinforcement. Eur J Neurosci 50(3):2180\u20132200","journal-title":"Eur J Neurosci"},{"key":"4845_CR69","doi-asserted-by":"publisher","first-page":"18474","DOI":"10.3390\/ijms160818474","volume":"16","author":"Z Chilmonczyk","year":"2015","unstructured":"Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I (2015) Int J Mol Sci 16:18474\u201318506","journal-title":"Int J Mol Sci"},{"key":"4845_CR70","doi-asserted-by":"crossref","unstructured":"Yankelevitch-Yahav R, Franko M, Huly A, Doron R (2015) The forced swim test as a model of depressive-like behavior. J Vis Exp 97","DOI":"10.3791\/52587-v"},{"key":"4845_CR71","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/0269881108091587","volume":"23","author":"J Andreasen","year":"2008","unstructured":"Andreasen J, Olsen G, Redrobe J (2008) Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 23:797\u2013804","journal-title":"J Psychopharmacol"},{"key":"4845_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/bs.irn.2015.07.004","volume":"124","author":"J Audrain-McGovern","year":"2015","unstructured":"Audrain-McGovern J, Leventhal AM, Strong DR (2015) The role of depression in the uptake and maintenance of cigarette smoking. Int Rev Neurobiol 124:209\u2013243","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"4845_CR73","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41533-023-00333-y","volume":"33","author":"S Chirila","year":"2023","unstructured":"Chirila S, Antohe A, Isar C, Panaitescu C, Malpass A (2023) Romanian young adult perceptions on using heated tobacco products following exposure to direct marketing methods. NPJ Prim Care Respir Med 33(1):8","journal-title":"NPJ Prim Care Respir Med"},{"key":"4845_CR74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neubiorev.2017.08.018","volume":"84","author":"JA Gandelman","year":"2018","unstructured":"Gandelman JA, Newhouse P, Taylor WD (2018) Nicotine and networks: potential for enhancement of mood and cognition in late-life depression. Neurosci Biobehav Rev 84:289\u2013298","journal-title":"Neurosci Biobehav Rev"},{"key":"4845_CR75","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/cells10061548","volume":"10","author":"MN Mithaiwala","year":"2021","unstructured":"Mithaiwala MN, Santana-Coelho D, Porter GA, O\u2019Connor JC (2021) Cells 10:1548","journal-title":"Cells"},{"issue":"11 Pt A","key":"4845_CR76","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.bbagen.2016.07.002","volume":"1860","author":"PB Larkin","year":"2016","unstructured":"Larkin PB, Sathyasaikumar KV, Notarangelo FM, Funakoshi H, Nakamura T, Schwarcz R, Muchowski PJ (2016) Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta 1860(11 Pt A):2345\u20132354","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4845_CR77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41398-021-01688-x","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Shi H, Yang G, Yang Y, Li W, Song M, Shao M, Su X, Lv L (2021) Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia. Transl Psychiatry 11(1):595","journal-title":"Transl Psychiatry"},{"key":"4845_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/antiox15020261","author":"L Juh\u00e1sz","year":"2026","unstructured":"Juh\u00e1sz L, Galla Z, Tanaka M, V\u00e9csei L (2026) Receptor-mitochondria crosstalk in the kynurenine metabolic pathway: integrating metabolomics and clinical mass spectrometry. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox15020261","journal-title":"Antioxidants (Basel)"},{"key":"4845_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.586520","volume":"12","author":"R Mart\u00edn R\u00edos","year":"2021","unstructured":"Mart\u00edn R\u00edos R, L\u00f3pez-Torrecillas F, Mart\u00edn Tamayo I (2021) Executive functions in tobacco use disorder: new challenges and opportunities. Front Psychiatry 12:586520","journal-title":"Front Psychiatry"},{"key":"4845_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.909961","author":"S Eickhoff","year":"2022","unstructured":"Eickhoff S, Franzen L, Korda A, Rogg H, Trulley V-N, Borgwardt S, Avram M (2022) The basal forebrain cholinergic nuclei and their relevance to schizophrenia and other psychotic disorders. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2022.909961","journal-title":"Front Psychiatry"},{"issue":"7","key":"4845_CR81","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00213-014-3754-4","volume":"232","author":"RD Cole","year":"2015","unstructured":"Cole RD, Poole RL, Guzman DM, Gould TJ, Parikh V (2015) Contributions of \u03b22 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology 232(7):1207\u20131217","journal-title":"Psychopharmacology"},{"issue":"2","key":"4845_CR82","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neubiorev.2010.05.002","volume":"35","author":"O George","year":"2010","unstructured":"George O, Koob GF (2010) Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev 35(2):232\u2013247","journal-title":"Neurosci Biobehav Rev"},{"issue":"1\u20133","key":"4845_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2016.01.020","volume":"171","author":"V Parikh","year":"2016","unstructured":"Parikh V, Kutlu MG, Gould TJ (2016) nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophr Res 171(1\u20133):1\u201315","journal-title":"Schizophr Res"},{"key":"4845_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cells13030237","author":"A Crestini","year":"2024","unstructured":"Crestini A, Carbone E, Rivabene R, Ancidoni A, Rosa P, Tata AM, Fabrizi E, Locuratolo N, Vanacore N, Lacorte E, Piscopo P (2024) A systematic review on drugs acting as nicotinic acetylcholine receptor agonists in the treatment of dementia. Cells. https:\/\/doi.org\/10.3390\/cells13030237","journal-title":"Cells"},{"issue":"4","key":"4845_CR85","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-003-1614-8","volume":"171","author":"HK White","year":"2004","unstructured":"White HK, Levin ED (2004) Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology 171(4):465\u2013471","journal-title":"Psychopharmacology"},{"key":"4845_CR86","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251355112","author":"N Kumari","year":"2025","unstructured":"Kumari N, Cooke LE, Olsen AL (2025) Proposed mechanisms of neuroprotection for nicotine in Parkinson\u2019s disease. J Parkinsons Dis. https:\/\/doi.org\/10.1177\/1877718X251355112","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"4845_CR87","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","volume":"60","author":"LZ Huang","year":"2011","unstructured":"Huang LZ, Campos C, Ly J, Ivy Carroll F, Quik M (2011) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60(6):861\u2013868","journal-title":"Neuropharmacology"},{"issue":"11","key":"4845_CR88","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1176\/ajp.155.11.1490","volume":"155","author":"GW Dalack","year":"1998","unstructured":"Dalack GW, Healy DJ, Meador-Woodruff JH (1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155(11):1490\u20131501","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4845_CR89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bcp.2015.07.027","volume":"97","author":"AV Terry Jr","year":"2015","unstructured":"Terry AV Jr., Callahan PM, Hernandez CM (2015) Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochem Pharmacol 97(4):388\u2013398","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"4845_CR90","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.bcp.2007.07.002","volume":"74","author":"TE Wilens","year":"2007","unstructured":"Wilens TE, Decker MW (2007) Neuronal nicotinic receptor agonists for the treatment of attention-deficit\/hyperactivity disorder: focus on cognition. Biochem Pharmacol 74(8):1212\u20131223","journal-title":"Biochem Pharmacol"},{"key":"4845_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2016.00160","volume":"7","author":"M Besson","year":"2016","unstructured":"Besson M, Forget B (2016) Cognitive dysfunction, affective states, and vulnerability to nicotine addiction: a multifactorial perspective. Front Psychiatry 7:160","journal-title":"Front Psychiatry"},{"issue":"5","key":"4845_CR92","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn2635","volume":"10","author":"M Sarter","year":"2009","unstructured":"Sarter M, Parikh V, Howe WM (2009) Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci 10(5):383\u2013390","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"4845_CR93","doi-asserted-by":"publisher","first-page":"CD010744","DOI":"10.1002\/14651858.CD010744.pub2","volume":"2016","author":"EA van Eerd","year":"2016","unstructured":"van Eerd EA, van der Meer RM, van Schayck OC, Kotz D (2016) Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016(8):CD010744","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4845_CR94","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1399","volume":"20","author":"M Rahman","year":"2024","unstructured":"Rahman M, Alatiqi M, Al Jarallah M, Hussain MY, Monayem A, Panduranga P, Rajan R (2024) Cardiovascular effects of smoking and smoking cessation: a 2024 update. Glob Heart 20(1):15","journal-title":"Glob Heart"},{"issue":"1","key":"4845_CR95","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00213-019-05363-4","volume":"237","author":"B Hahn","year":"2020","unstructured":"Hahn B, Shrieves ME, Olmstead CK, Yuille MB, Chiappelli JJ, Pereira EFR, Albuquerque EX, Fawcett WP (2020) Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects. Psychopharmacology 237(1):219\u2013230","journal-title":"Psychopharmacology"},{"key":"4845_CR96","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12137","author":"JA Gandelman","year":"2018","unstructured":"Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD (2018) Transdermal nicotine for the treatment of mood and cognitive symptoms in nonsmokers with late-life depression. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.18m12137","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"4845_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1617-9625-3-2-17","volume":"3","author":"T Korhonen","year":"2006","unstructured":"Korhonen T, Kinnunen TH, Garvey AJ (2006) Impact of nicotine replacement therapy on post-cessation mood profile by pre-cessation depressive symptoms. Tob Induc Dis 3(2):17\u201333","journal-title":"Tob Induc Dis"},{"issue":"5","key":"4845_CR98","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","volume":"70","author":"PM Cinciripini","year":"2013","unstructured":"Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Brown VL, Engelmann JM, Wetter DW (2013) Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 70(5):522\u2013533","journal-title":"JAMA Psychiatry"},{"key":"4845_CR99","doi-asserted-by":"publisher","first-page":"204512532110006","DOI":"10.1177\/20451253211000612","volume":"11","author":"MM Qureshi","year":"2021","unstructured":"Qureshi MM, Young AH (2021) Hamlet\u2019s augury: how to manage discontinuation of mood stabilizers in bipolar disorder. Ther Adv Psychopharmacol 11:20451253211000612","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"4845_CR100","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00213-009-1486-7","volume":"204","author":"A Cohen","year":"2009","unstructured":"Cohen A, Young RW, Velazquez MA, Groysman M, Noorbehesht K, Ben-Shahar OM, Ettenberg A (2009) Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict. Psychopharmacology (Berl) 204(3):541\u2013549","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"4845_CR101","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.tips.2010.09.004","volume":"31","author":"YS Mineur","year":"2010","unstructured":"Mineur YS, Picciotto MR (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31(12):580\u2013586","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"4845_CR102","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Arachchige A (2023) Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 10(3):200\u2013231","journal-title":"AIMS Neurosci"},{"key":"4845_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104154","volume":"82","author":"SC Larsson","year":"2022","unstructured":"Larsson SC, Burgess S (2022) Appraising the causal role of smoking in multiple diseases: a systematic review and meta-analysis of Mendelian randomization studies. EBioMedicine 82:104154","journal-title":"EBioMedicine"},{"key":"4845_CR104","first-page":"340","volume":"6","author":"GE Barreto","year":"2014","unstructured":"Barreto GE, Iarkov A, Moran VE (2014) Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson\u2019s disease. Front Aging Neurosci 6:340","journal-title":"Front Aging Neurosci"},{"key":"4845_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111732","author":"M Vidovi\u0107","year":"2022","unstructured":"Vidovi\u0107 M, Rikalovic MG (2022) Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches. Cells. https:\/\/doi.org\/10.3390\/cells11111732","journal-title":"Cells"},{"issue":"9","key":"4845_CR106","doi-asserted-by":"publisher","first-page":"EVIDoa2200311","DOI":"10.1056\/EVIDoa2200311","volume":"2","author":"WH Oertel","year":"2023","unstructured":"Oertel WH, M\u00fcller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT (2023) Transdermal nicotine treatment and progression of early Parkinson\u2019s disease. NEJM Evid 2(9):EVIDoa2200311","journal-title":"NEJM Evid"},{"issue":"8","key":"4845_CR107","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","volume":"82","author":"DK Williams","year":"2011","unstructured":"Williams DK, Wang J, Papke RL (2011) Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 82(8):915\u2013930","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"4845_CR108","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","volume":"74","author":"C Gotti","year":"2004","unstructured":"Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74(6):363\u2013396","journal-title":"Prog Neurobiol"},{"key":"4845_CR109","doi-asserted-by":"crossref","unstructured":"Alhowail A (2021) Molecular insights into the benefits of nicotine on memory and cognition (Review). Mol Med Rep 23(6)","DOI":"10.3892\/mmr.2021.12037"},{"issue":"13","key":"4845_CR110","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","volume":"73","author":"HO Kalkman","year":"2016","unstructured":"Kalkman HO, Feuerbach D (2016) Modulatory effects of \u03b17 nAChRs on the immune system and its relevance for CNS disorders. Cell Mol Life Sci 73(13):2511\u20132530","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4845_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD (2020) Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 19(1):15\u201333","journal-title":"World Psychiatry"},{"key":"4845_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108053","volume":"170","author":"AV Terry","year":"2020","unstructured":"Terry AV Jr., Callahan PM (2020) \u03b17 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future. Neuropharmacology 170:108053","journal-title":"Neuropharmacology"},{"issue":"3","key":"4845_CR113","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ntr\/nty034","volume":"21","author":"JR Tregellas","year":"2019","unstructured":"Tregellas JR, Wylie KP (2019) Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia. Nicotine Tob Res 21(3):349\u2013356","journal-title":"Nicotine Tob Res"},{"key":"4845_CR114","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.brainres.2015.02.044","volume":"1611","author":"KE Stevens","year":"2015","unstructured":"Stevens KE, Zheng L, Floyd KL, Stitzel JA (2015) Maximizing the effect of an \u03b17 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits. Brain Res 1611:8\u201317","journal-title":"Brain Res"},{"issue":"1","key":"4845_CR115","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70061","volume":"137","author":"JH Magnussen","year":"2025","unstructured":"Magnussen JH (2025) Therapeutic targeting of the \u03b17 nicotinic receptor: challenges and prospects for cognitive improvement in Alzheimer\u2019s and schizophrenia. Basic Clin Pharmacol Toxicol 137(1):e70061","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4845_CR116","doi-asserted-by":"crossref","unstructured":"Chou HH, Twamley E, Swerdlow NR (2012) Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol (213):81\u2013111","DOI":"10.1007\/978-3-642-25758-2_4"},{"issue":"5","key":"4845_CR117","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1016\/j.jpeds.2009.01.018","volume":"154","author":"AF Arnsten","year":"2009","unstructured":"Arnsten AF (2009) The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154(5):I-s43","journal-title":"J Pediatr"},{"key":"4845_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroscience.2012.10.067","volume":"230","author":"IA Mendez","year":"2013","unstructured":"Mendez IA, Damborsky JC, Winzer-Serhan UH, Bizon JL, Setlow B (2013) \u03914\u03b22 and \u03b17 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks. Neuroscience 230:121\u2013131","journal-title":"Neuroscience"},{"issue":"3","key":"4845_CR119","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pbb.2007.05.009","volume":"87","author":"S Semenova","year":"2007","unstructured":"Semenova S, Stolerman IP, Markou A (2007) Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav 87(3):360\u2013368","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"4845_CR120","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2017.01.013","volume":"27","author":"A Hayward","year":"2017","unstructured":"Hayward A, Adamson L, Neill JC (2017) Partial agonism at the \u03b17 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats. Eur Neuropsychopharmacol 27(4):325\u2013335","journal-title":"Eur Neuropsychopharmacol"},{"issue":"16","key":"4845_CR121","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1113\/JP270492","volume":"593","author":"M Yuan","year":"2015","unstructured":"Yuan M, Cross SJ, Loughlin SE, Leslie FM (2015) Nicotine and the adolescent brain. J Physiol 593(16):3397\u20133412","journal-title":"J Physiol"},{"key":"4845_CR122","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.npp.1300881","volume":"31","author":"R Smith","year":"2006","unstructured":"Smith R, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S, Khan A (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacol: Official Publication Am Coll Neuropsychopharmacol 31:637\u2013643","journal-title":"Neuropsychopharmacol: Official Publication Am Coll Neuropsychopharmacol"},{"issue":"12","key":"4845_CR123","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1176\/ajp.156.12.1931","volume":"156","author":"TE Wilens","year":"1999","unstructured":"Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156(12):1931\u20131937","journal-title":"Am J Psychiatry"},{"issue":"12","key":"4845_CR124","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40263-014-0208-9","volume":"28","author":"AS Potter","year":"2014","unstructured":"Potter AS, Schaubhut G, Shipman M (2014) Targeting the nicotinic cholinergic system to treat attention-deficit\/hyperactivity disorder: rationale and progress to date. CNS Drugs 28(12):1103\u20131113","journal-title":"CNS Drugs"},{"key":"4845_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/genes13040646","author":"M Kamran","year":"2022","unstructured":"Kamran M, Bibi F, Ur Rehman A, Morris DW (2022) Major depressive disorder: existing hypotheses about pathophysiological mechanisms and new genetic findings. Genes (Basel). https:\/\/doi.org\/10.3390\/genes13040646","journal-title":"Genes (Basel)"},{"issue":"20","key":"4845_CR126","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1021\/jm401937a","volume":"57","author":"LF Yu","year":"2014","unstructured":"Yu LF, Zhang HK, Caldarone BJ, Eaton JB, Lukas RJ, Kozikowski AP (2014) Recent developments in novel antidepressants targeting \u03b14\u03b22-nicotinic acetylcholine receptors. J Med Chem 57(20):8204\u20138223","journal-title":"J Med Chem"},{"key":"4845_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02546","volume":"10","author":"R Xue","year":"2019","unstructured":"Xue R, Wan Y, Sun X, Zhang X, Gao W, Wu W (2019) Nicotinic mitigation of neuroinflammation and oxidative stress after chronic sleep deprivation. Front Immunol 10:2546","journal-title":"Front Immunol"},{"issue":"4","key":"4845_CR128","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/BF02246496","volume":"121","author":"RJ Sal\u00edn-Pascual","year":"1995","unstructured":"Sal\u00edn-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Col\u00edn R (1995) Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology 121(4):476\u2013479","journal-title":"Psychopharmacology"},{"issue":"5","key":"4845_CR129","first-page":"Cd006103","volume":"2016","author":"K Cahill","year":"2016","unstructured":"Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016(5):Cd006103","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4845_CR130","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/add.15338","volume":"116","author":"KH Thomas","year":"2021","unstructured":"Thomas KH, Davies NM, Taylor AE, Taylor GMJ, Gunnell D, Martin RM, Douglas I (2021) Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case-cross-over study. Addiction 116(6):1532\u20131545","journal-title":"Addiction"},{"issue":"5","key":"4845_CR131","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41582-022-00635-8","volume":"18","author":"KJ Ressler","year":"2022","unstructured":"Ressler KJ, Berretta S, Bolshakov VY, Rosso IM, Meloni EG, Rauch SL, Carlezon WA Jr. (2022) Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat Rev Neurol 18(5):273\u2013288","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"4845_CR132","doi-asserted-by":"publisher","first-page":"263","DOI":"10.31887\/DCNS.2011.13.2\/jsherin","volume":"13","author":"JE Sherin","year":"2011","unstructured":"Sherin JE, Nemeroff CB (2011) Post-traumatic stress disorder: the neurobiological impact of psychological trauma. Dialogues Clin Neurosci 13(3):263\u2013278","journal-title":"Dialogues Clin Neurosci"},{"issue":"2","key":"4845_CR133","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tins.2021.11.006","volume":"45","author":"AC Letsinger","year":"2022","unstructured":"Letsinger AC, Gu Z, Yakel JL (2022) \u03b17 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity. Trends Neurosci 45(2):145\u2013157","journal-title":"Trends Neurosci"},{"key":"4845_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106764","volume":"191","author":"AV Terry","year":"2023","unstructured":"Terry AV Jr., Jones K, Bertrand D (2023) Nicotinic acetylcholine receptors in neurological and psychiatric diseases. Pharmacol Res 191:106764","journal-title":"Pharmacol Res"},{"issue":"6","key":"4845_CR135","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2796.2009.02098.x","volume":"265","author":"M Rosas-Ballina","year":"2009","unstructured":"Rosas-Ballina M, Tracey KJ (2009) Cholinergic control of inflammation. J Intern Med 265(6):663\u2013679","journal-title":"J Intern Med"},{"issue":"11","key":"4845_CR136","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1111\/bph.13090","volume":"172","author":"SM Anderson","year":"2015","unstructured":"Anderson SM, Brunzell DH (2015) Anxiolytic-like and anxiogenic-like effects of nicotine are regulated via diverse action at \u03b22*nicotinic acetylcholine receptors. Br J Pharmacol 172(11):2864\u20132877","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"4845_CR137","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neuropharm.2008.07.020","volume":"56","author":"CJ Heath","year":"2009","unstructured":"Heath CJ, Picciotto MR (2009) Nicotine-induced plasticity during development: modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing. Neuropharmacology 56(Suppl 1):254\u2013262","journal-title":"Neuropharmacology"},{"issue":"3","key":"4845_CR138","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11481-023-10064-z","volume":"18","author":"A Govindula","year":"2023","unstructured":"Govindula A, Ranadive N, Nampoothiri M, Rao CM, Arora D, Mudgal J (2023) Emphasizing the crosstalk between inflammatory and neural signaling in post-traumatic stress disorder (PTSD). J Neuroimmune Pharmacol 18(3):248\u2013266","journal-title":"J Neuroimmune Pharmacol"},{"key":"4845_CR139","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.addbeh.2018.04.024","volume":"84","author":"I Pericot-Valverde","year":"2018","unstructured":"Pericot-Valverde I, Elliott RJ, Miller ME, Tidey JW, Gaalema DE (2018) Posttraumatic stress disorder and tobacco use: a systematic review and meta-analysis. Addict Behav 84:238\u2013247","journal-title":"Addict Behav"},{"issue":"22","key":"4845_CR140","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1001\/jama.2010.1769","volume":"304","author":"M McFall","year":"2010","unstructured":"McFall M, Saxon AJ, Malte CA, Chow B, Bailey S, Baker DG, Beckham JC, Boardman KD, Carmody TP, Joseph AM, Smith MW, Shih MC, Lu Y, Holodniy M, Lavori PW (2010) Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA 304(22):2485\u20132493","journal-title":"JAMA"},{"key":"4845_CR141","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.irn.2015.08.004","volume":"124","author":"MG Kutlu","year":"2015","unstructured":"Kutlu MG, Parikh V, Gould TJ (2015) Nicotine addiction and psychiatric disorders. Int Rev Neurobiol 124:171\u2013208","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"4845_CR142","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.physbeh.2011.04.043","volume":"104","author":"EC Donny","year":"2011","unstructured":"Donny EC, Caggiula AR, Weaver MT, Levin ME, Sved AF (2011) The reinforcement-enhancing effects of nicotine: implications for the relationship between smoking, eating and weight. Physiol Behav 104(1):143\u2013148","journal-title":"Physiol Behav"},{"key":"4845_CR143","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-319-13482-6_2","volume":"24","author":"LE Rupprecht","year":"2015","unstructured":"Rupprecht LE, Smith TT, Schassburger RL, Buffalari DM, Sved AF, Donny EC (2015) Behavioral mechanisms underlying nicotine reinforcement. Curr Top Behav Neurosci 24:19\u201353","journal-title":"Curr Top Behav Neurosci"},{"key":"4845_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162051","author":"AS Vall\u00e9s","year":"2023","unstructured":"Vall\u00e9s AS, Barrantes FJ (2023) Nicotinic acetylcholine receptor dysfunction in addiction and in some neurodegenerative and neuropsychiatric diseases. Cells (Basel). https:\/\/doi.org\/10.3390\/cells12162051","journal-title":"Cells (Basel)"},{"key":"4845_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109418","volume":"226","author":"N Singewald","year":"2023","unstructured":"Singewald N, Sartori SB, Reif A, Holmes A (2023) Alleviating anxiety and taming trauma: novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology 226:109418","journal-title":"Neuropharmacology"},{"issue":"8","key":"4845_CR146","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.bcp.2011.07.067","volume":"82","author":"J Wu","year":"2011","unstructured":"Wu J, Lukas RJ (2011) Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem Pharmacol 82(8):800\u2013807","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4845_CR147","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00018-024-05374-1","volume":"81","author":"N Mukhtasimova","year":"2024","unstructured":"Mukhtasimova N, Bouzat C, Sine SM (2024) Novel interplay between agonist and calcium binding sites modulates drug potentiation of \u03b17 acetylcholine receptor. Cell Mol Life Sci 81(1):332","journal-title":"Cell Mol Life Sci"},{"issue":"30","key":"4845_CR148","doi-asserted-by":"publisher","first-page":"10891","DOI":"10.1523\/JNEUROSCI.0937-11.2011","volume":"31","author":"TM McGranahan","year":"2011","unstructured":"McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK (2011) \u03b14\u03b22 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J Neurosci 31(30):10891\u201310902","journal-title":"J Neurosci"},{"key":"4845_CR149","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/978-94-007-2888-2_27","volume":"740","author":"VV Uteshev","year":"2012","unstructured":"Uteshev VV (2012) \u03b17 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum. Adv Exp Med Biol 740:603\u2013638","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"4845_CR150","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/15672050113109990132","volume":"10","author":"M Oz","year":"2013","unstructured":"Oz M, Lorke DE, Yang KH, Petroianu G (2013) On the interaction of \u03b2-amyloid peptides and \u03b17-nicotinic acetylcholine receptors in Alzheimer\u2019s disease. Curr Alzheimer Res 10(6):618\u2013630","journal-title":"Curr Alzheimer Res"},{"key":"4845_CR151","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neuropharm.2016.02.032","volume":"107","author":"ND Andersen","year":"2016","unstructured":"Andersen ND, Nielsen BE, Corradi J, Tolosa MF, Feuerbach D, Arias HR, Bouzat C (2016) Exploring the positive allosteric modulation of human \u03b17 nicotinic receptors from a single-channel perspective. Neuropharmacology 107:189\u2013200","journal-title":"Neuropharmacology"},{"key":"4845_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2016.1","volume":"2","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Barrantes FJ (2016) Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson\u2019s disease. NPJ Park Dis 2:16001","journal-title":"NPJ Park Dis"},{"issue":"8","key":"4845_CR153","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mds.25028","volume":"27","author":"M Quik","year":"2012","unstructured":"Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson\u2019s disease. Mov Disord 27(8):947\u2013957","journal-title":"Mov Disord"},{"issue":"6","key":"4845_CR154","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1523\/JNEUROSCI.21-06-01819.2001","volume":"21","author":"B Buisson","year":"2001","unstructured":"Buisson B, Bertrand D (2001) Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J Neurosci 21(6):1819\u20131829","journal-title":"J Neurosci"},{"key":"4845_CR155","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/B978-0-12-420118-7.00013-5","volume":"69","author":"PA Crooks","year":"2014","unstructured":"Crooks PA, Bardo MT, Dwoskin LP (2014) Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol 69:513\u2013551","journal-title":"Adv Pharmacol"},{"key":"4845_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100402","volume":"296","author":"JP Roberts","year":"2021","unstructured":"Roberts JP, Stokoe SA, Sathler MF, Nichols RA, Kim S (2021) Selective coactivation of \u03b17- and \u03b14\u03b22-nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction. J Biol Chem 296:100402","journal-title":"J Biol Chem"},{"issue":"4","key":"4845_CR157","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbrc.2016.09.062","volume":"483","author":"SV Salazar","year":"2017","unstructured":"Salazar SV, Strittmatter SM (2017) Cellular prion protein as a receptor for amyloid-\u03b2 oligomers in Alzheimer\u2019s disease. Biochem Biophys Res Commun 483(4):1143\u20131147","journal-title":"Biochem Biophys Res Commun"},{"key":"4845_CR158","unstructured":"Parada Bustamante A, Orihuela PA, Molina C, C\u00e1rdenas H, Reuqu\u00e9n P, Valencia C, Rinc\u00f3n R (2013) Hydroxyestradiols and methoxyestradiols as endogenous factors associated to physiological and physiopathological conditions"},{"issue":"7","key":"4845_CR159","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/life15071032","volume":"15","author":"K Rennie","year":"2025","unstructured":"Rennie K (2025) Neuronal and glial \u03b17 nicotinic acetylcholine receptors: role in Alzheimer\u2019s disease pathophysiology. Life 15(7):1032","journal-title":"Life"},{"issue":"3","key":"4845_CR160","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1124\/pharmrev.120.000097","volume":"73","author":"RL Papke","year":"2021","unstructured":"Papke RL, Horenstein NA (2021) Therapeutic targeting of \u03b17 nicotinic acetylcholine receptors. Pharmacol Rev 73(3):1118\u20131149","journal-title":"Pharmacol Rev"},{"issue":"12","key":"4845_CR161","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","volume":"59","author":"S Leonard","year":"2002","unstructured":"Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R (2002) Association of promoter variants in the \u03b17 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59(12):1085\u20131096","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"4845_CR162","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00018-013-1481-3","volume":"71","author":"E Proulx","year":"2014","unstructured":"Proulx E, Piva M, Tian MK, Bailey CD, Lambe EK (2014) Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex. Cell Mol Life Sci 71(7):1225\u20131244","journal-title":"Cell Mol Life Sci"},{"key":"4845_CR163","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fncir.2014.00033","volume":"8","author":"KL Clark","year":"2014","unstructured":"Clark KL, Noudoost B (2014) The role of prefrontal catecholamines in attention and working memory. Front Neural Circuits 8:33","journal-title":"Front Neural Circuits"},{"key":"4845_CR164","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.bcp.2009.05.033","volume":"78","author":"H Rollema","year":"2009","unstructured":"Rollema H, Haj\u00f3s M, Seymour P, Kozak R, Majchrzak M, Guanowsky V, Horner W, Chapin D, Hoffmann W, Johnson D, McLean S, Freeman J, Williams K (2009) Preclinical pharmacology of the \u03b14\u03b22 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 78:813\u2013824","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"4845_CR165","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41380-025-03110-0","volume":"30","author":"LM Reynolds","year":"2025","unstructured":"Reynolds LM, Faure P, Barik J (2025) Adolescent nicotine exposure and persistent neurocircuitry changes: unveiling lifelong psychiatric risks. Mol Psychiatry 30(11):5534\u20135545","journal-title":"Mol Psychiatry"},{"issue":"3","key":"4845_CR166","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.pbb.2012.11.005","volume":"103","author":"KK Ryan","year":"2013","unstructured":"Ryan KK, Dube SL, Potter AS (2013) Rate dependent effects of acute nicotine on risk taking in young adults are not related to ADHD diagnosis. Pharmacol Biochem Behav 103(3):652\u2013658","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"4845_CR167","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.bcp.2013.07.021","volume":"86","author":"ED Levin","year":"2013","unstructured":"Levin ED (2013) Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 86(8):1145\u20131152","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4845_CR168","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1124\/molpharm.122.000591","volume":"103","author":"RL Papke","year":"2023","unstructured":"Papke RL, Stokes C (2023) Insights into the differential desensitization of \u03b14\u03b22 nicotinic acetylcholine receptor isoforms obtained with positive allosteric modulation of mutant receptors. Mol Pharmacol 103(2):63\u201376","journal-title":"Mol Pharmacol"},{"issue":"1","key":"4845_CR169","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5334\/gh.1292","volume":"19","author":"EU Dorotheo","year":"2024","unstructured":"Dorotheo EU, Arora M, Banerjee A, Bianco E, Cheah NP, Dalmau R, Eissenberg T, Hasegawa K, Naidoo P, Nazir NT, Newby LK, Obeidat N, Skipalskyi A, St\u0119pi\u0144ska J, Willett J, Wang Y (2024) Nicotine and cardiovascular health: when poison is addictive - a WHF policy brief. Glob Heart 19(1):14","journal-title":"Glob Heart"},{"key":"4845_CR170","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.05.010","volume":"103","author":"L Gong","year":"2018","unstructured":"Gong L, He C, Zhang H, Zhang H, Zhang Z, Xie C (2018) Disrupted reward and cognitive control networks contribute to anhedonia in depression. J Psychiatr Res 103:61\u201368","journal-title":"J Psychiatr Res"},{"issue":"5","key":"4845_CR171","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41380-018-0219-x","volume":"24","author":"SC Dulawa","year":"2019","unstructured":"Dulawa SC, Janowsky DS (2019) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry 24(5):694\u2013709","journal-title":"Mol Psychiatry"},{"key":"4845_CR172","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/cells10061283","volume":"10","author":"EV Filatova","year":"2021","unstructured":"Filatova EV, Shadrina MI, Slominsky PA (2021) Cells 10:1283","journal-title":"Cells"},{"issue":"4","key":"4845_CR173","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.62347\/MOBZ7773","volume":"17","author":"N Patidar","year":"2025","unstructured":"Patidar N, Navale AM, Parsaila N, Sharma D, Nahar P, Shinde S, Solanki N, Shelke A (2025) Nicotine replacement therapy: insights into the mechanisms and potential of nicotine receptor pathway. Am J Transl Res 17(4):2396\u20132410","journal-title":"Am J Transl Res"},{"issue":"28","key":"4845_CR174","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.2174\/092986708786848703","volume":"15","author":"G Sharma","year":"2008","unstructured":"Sharma G, Vijayaraghavan S (2008) Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. Curr Med Chem 15(28):2921\u20132932","journal-title":"Curr Med Chem"},{"key":"4845_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191558","author":"M Pinzi","year":"2025","unstructured":"Pinzi M, Fagiolini A, Koukouna D, Gualtieri G, Rescalli MB, Pierini C, Pardossi S, Patrizio B, Cuomo A (2025) Inflammatory and immune biomarkers in mood disorders: from mechanistic pathways to clinical translation. Cells (Basel). https:\/\/doi.org\/10.3390\/cells14191558","journal-title":"Cells (Basel)"},{"key":"4845_CR176","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.neuropharm.2016.02.028","volume":"105","author":"M Udakis","year":"2016","unstructured":"Udakis M, Wright VL, Wonnacott S, Bailey CP (2016) Integration of inhibitory and excitatory effects of \u03b17 nicotinic acetylcholine receptor activation in the prelimbic cortex regulates network activity and plasticity. Neuropharmacology 105:618\u2013629","journal-title":"Neuropharmacology"},{"key":"4845_CR177","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.3390\/ijms26073210","volume":"26","author":"E ElNebrisi","year":"2025","unstructured":"ElNebrisi E, Lozon Y, Oz M (2025) Int J Mol Sci 26:3210","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4845_CR178","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cbpra.2017.12.003","volume":"26","author":"JF McGuire","year":"2019","unstructured":"McGuire JF, Storch EA (2019) An inhibitory learning approach to cognitive-behavioral therapy for children and adolescents. Cogn Behav Pract 26(1):214\u2013224","journal-title":"Cogn Behav Pract"},{"issue":"1","key":"4845_CR179","doi-asserted-by":"publisher","DOI":"10.1515\/tnsci-2022-0345","volume":"15","author":"L Peng","year":"2024","unstructured":"Peng L, Li H, Zhang C, Jiang W (2024) Activating \u03b17nAChR suppresses systemic inflammation by mitigating neuroinflammation of the medullary visceral zone in sepsis in a rat model. Transl Neurosci 15(1):20220345","journal-title":"Transl Neurosci"},{"issue":"24\u201325","key":"4845_CR180","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.lfs.2007.01.002","volume":"80","author":"M Gallowitsch-Puerta","year":"2007","unstructured":"Gallowitsch-Puerta M, Pavlov VA (2007) Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci 80(24\u201325):2325\u20132329","journal-title":"Life Sci"},{"key":"4845_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1125492","volume":"17","author":"T Simon","year":"2023","unstructured":"Simon T, Kirk J, Dolezalova N, Guyot M, Panzolini C, Bondue A, Lavergne J, Hugues S, Hypolite N, Saeb-Parsy K, Perkins J, Macia E, Sridhar A, Vervoordeldonk MJ, Glaichenhaus N, Doneg\u00e1 M, Blancou P (2023) The cholinergic anti-inflammatory pathway inhibits inflammation without lymphocyte relay. Front Neurosci 17:1125492","journal-title":"Front Neurosci"},{"issue":"4","key":"4845_CR182","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17437199.2024.2330896","volume":"18","author":"A Shevorykin","year":"2024","unstructured":"Shevorykin A, Hyland BM, Robles D, Ji M, Vantucci D, Bensch L, Thorner H, Marion M, Liskiewicz A, Carl E, Ostroff JS, Sheffer CE (2024) Tobacco use, trauma exposure and PTSD: a systematic review. Health Psychol Rev 18(4):649\u2013680","journal-title":"Health Psychol Rev"},{"issue":"15","key":"4845_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157050","volume":"26","author":"M Pinkiewicz","year":"2025","unstructured":"Pinkiewicz M, Zaczy\u0144ski A, Walecki J, Zawadzki M (2025) Beyond the walls of Troy: a scoping review on pharmacological strategies to enhance drug delivery across the blood\u2013brain barrier and blood\u2013tumor barrier. Int J Mol Sci 26(15):7050","journal-title":"Int J Mol Sci"},{"issue":"7329","key":"4845_CR184","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nature09746","volume":"469","author":"T Warne","year":"2011","unstructured":"Warne T, Moukhametzianov R, Baker JG, Nehm\u00e9 R, Edwards PC, Leslie AG, Schertler GF, Tate CG (2011) The structural basis for agonist and partial agonist action on a \u03b2(1)-adrenergic receptor. Nature 469(7329):241\u2013244","journal-title":"Nature"},{"issue":"1","key":"4845_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62212-z","volume":"16","author":"WAC Burger","year":"2025","unstructured":"Burger WAC, Mobbs JI, Rana B, Wang J, Joshi K, Gentry PR, Yeasmin M, Venugopal H, Bender AM, Lindsley CW, Miao Y, Christopoulos A, Valant C, Thal DM (2025) Cryo-EM reveals an extrahelical allosteric binding site at the M(5) mAChR. Nat Commun 16(1):7046","journal-title":"Nat Commun"},{"issue":"4","key":"4845_CR186","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1002\/prp2.70131","volume":"13","author":"MS Hossain","year":"2025","unstructured":"Hossain MS, Hussain MH (2025) Multi-target drug design in alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect 13(4):e70131","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"4845_CR187","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ntr\/nty189","volume":"21","author":"PA Newhouse","year":"2019","unstructured":"Newhouse PA (2019) Therapeutic applications of nicotinic stimulation: successes, failures, and future prospects. Nicotine Tob Res 21(3):345\u2013348","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"4845_CR188","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pain.2010.01.007","volume":"149","author":"B Gao","year":"2010","unstructured":"Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, van der Valk M, Deng H, Guo W, Lehto SG, Matson D, McDermott JS, Knop J, Gaida K, Cao L, Waldon D, Albrecht BK, Boezio AA, Copeland KW, Harmange JC, Springer SK, Malmberg AB, McDonough SI (2010) Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain 149(1):33\u201349","journal-title":"Pain"},{"issue":"3","key":"4845_CR189","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bcpt.12361","volume":"116","author":"M Grupe","year":"2015","unstructured":"Grupe M, Grunnet M, Bastlund JF, Jensen AA (2015) Targeting \u03b14\u03b22 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Basic Clin Pharmacol Toxicol 116(3):187\u2013200","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"4845_CR190","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J (2025) Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Therapy 10(1):74","journal-title":"Signal Transduct Target Therapy"},{"key":"4845_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031270","author":"D Manetti","year":"2023","unstructured":"Manetti D, Dei S, Arias HR, Braconi L, Gabellini A, Teodori E, Romanelli MN (2023) Recent advances in the discovery of nicotinic acetylcholine receptor allosteric modulators. Molecules. https:\/\/doi.org\/10.3390\/molecules28031270","journal-title":"Molecules"},{"key":"4845_CR192","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pneurobio.2016.01.002","volume":"144","author":"V Echeverria","year":"2016","unstructured":"Echeverria V, Yarkov A, Aliev G (2016) Positive modulators of the \u03b17 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer\u2019s disease. Prog Neurobiol 144:142\u2013157","journal-title":"Prog Neurobiol"},{"key":"4845_CR193","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7542","volume":"7","author":"K Pesti","year":"2019","unstructured":"Pesti K, Lukacs P, Mike A (2019) Type I-like behavior of the type II \u03b17 nicotinic acetylcholine receptor positive allosteric modulator A-867744. PeerJ 7:e7542","journal-title":"PeerJ"},{"issue":"17","key":"4845_CR194","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1523\/JNEUROSCI.5269-04.2005","volume":"25","author":"RS Hurst","year":"2005","unstructured":"Hurst RS, Haj\u00f3s M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann W, Piotrowski DW (2005) A novel positive allosteric modulator of the \u03b17 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25(17):4396\u20134405","journal-title":"J Neurosci"},{"issue":"13","key":"4845_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136450","volume":"26","author":"A Vialko","year":"2025","unstructured":"Vialko A, Cha\u0142upnik P, Szyma\u0144ska E (2025) Positive AMPA and kainate receptor modulators and their therapeutic potential in CNS diseases: a comprehensive review. Int J Mol Sci 26(13):6450","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4845_CR196","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.drudis.2016.08.001","volume":"21","author":"P Bawa","year":"2016","unstructured":"Bawa P, Pradeep P, Kumar P, Choonara YE, Modi G, Pillay V (2016) Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. Drug Discov Today 21(12):1886\u20131914","journal-title":"Drug Discov Today"},{"issue":"6","key":"4845_CR197","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/ph18060831","volume":"18","author":"E-E Katsoulaki","year":"2025","unstructured":"Katsoulaki E-E, Dimopoulos D, Hadjipavlou-Litina D (2025) Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegeneration diseases. Pharmaceuticals 18(6):831","journal-title":"Pharmaceuticals"},{"issue":"14","key":"4845_CR198","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/bph.14329","volume":"175","author":"NM Kowal","year":"2018","unstructured":"Kowal NM, Ahring PK, Liao VWY, Indurti DC, Harvey BS, O\u2019Connor SM, Chebib M, Olafsdottir ES, Balle T (2018) Galantamine is not a positive allosteric modulator of human \u03b14\u03b22 or \u03b17 nicotinic acetylcholine receptors. Br J Pharmacol 175(14):2911\u20132925","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4845_CR199","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/sj.bjp.0706221","volume":"145","author":"L Texid\u00f3","year":"2005","unstructured":"Texid\u00f3 L, Ros E, Mart\u00edn-Satu\u00e9 M, L\u00f3pez S, Aleu J, Marsal J, Solsona C (2005) Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145(5):672\u2013678","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4845_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0026-895X(25)08675-4","volume":"49","author":"A Schrattenholz","year":"1996","unstructured":"Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49(1):1\u20136","journal-title":"Mol Pharmacol"},{"issue":"4","key":"4845_CR201","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2174\/1570159X15666170818102108","volume":"16","author":"D Bagdas","year":"2018","unstructured":"Bagdas D, Gurun MS, Flood P, Papke RL, Damaj MI (2018) New insights on neuronal nicotinic acetylcholine receptors as targets for pain and inflammation: a focus on \u03b17 nAChRs. Curr Neuropharmacol 16(4):415\u2013425","journal-title":"Curr Neuropharmacol"},{"key":"4845_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144918","author":"S Mitra","year":"2020","unstructured":"Mitra S, Khatri SN, Maulik M, Bult-Ito A, Schulte M (2020) Allosterism of nicotinic acetylcholine receptors: therapeutic potential for neuroinflammation underlying brain trauma and degenerative disorders. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21144918","journal-title":"Int J Mol Sci"},{"key":"4845_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115648","volume":"224","author":"GB Armstrong","year":"2025","unstructured":"Armstrong GB, Graham H, Cheung A, Montaseri H, Burley GA, Karagiannis SN, Rattray Z (2025) Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers. Adv Drug Deliv Rev 224:115648","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"4845_CR204","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17460441.2017.1280024","volume":"12","author":"R Chaudhari","year":"2017","unstructured":"Chaudhari R, Tan Z, Huang B, Zhang S (2017) Computational polypharmacology: a new paradigm for drug discovery. Expert Opin Drug Discov 12(3):279\u2013291","journal-title":"Expert Opin Drug Discov"},{"key":"4845_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146996","author":"M Abdelsayed","year":"2025","unstructured":"Abdelsayed M (2025) AI-driven polypharmacology in small-molecule drug discovery. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26146996","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4845_CR206","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GF, Kim AJ (2016) Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des 22(9):1177\u20131193","journal-title":"Curr Pharm Des"},{"key":"4845_CR207","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/869269","volume":"2014","author":"RK Upadhyay","year":"2014","unstructured":"Upadhyay RK (2014) Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int 2014:869269","journal-title":"Biomed Res Int"},{"issue":"1","key":"4845_CR208","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuron.2011.03.014","volume":"70","author":"JM Miwa","year":"2011","unstructured":"Miwa JM, Freedman R, Lester HA (2011) Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 70(1):20\u201333","journal-title":"Neuron"},{"issue":"1","key":"4845_CR209","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/0971-5851.151771","volume":"36","author":"A Mishra","year":"2015","unstructured":"Mishra A, Chaturvedi P, Datta S, Sinukumar S, Joshi P, Garg A (2015) Harmful effects of nicotine. Indian J Med Paediatr Oncol 36(1):24\u201331","journal-title":"Indian J Med Paediatr Oncol"},{"key":"4845_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.883358","volume":"15","author":"JA Tello","year":"2022","unstructured":"Tello JA, Williams HE, Eppler RM, Steinhilb ML, Khanna M (2022) Animal models of neurodegenerative disease: recent advances in fly highlight innovative approaches to drug discovery. Front Mol Neurosci 15:883358","journal-title":"Front Mol Neurosci"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-026-04845-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:05:10Z","timestamp":1787569510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-026-04845-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":210,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4845"],"URL":"https:\/\/doi.org\/10.1007\/s11064-026-04845-0","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"229"}}